1. Anemia and Mineral Bone Disorder in Kidney Disease Patients: The Role of FGF-23 and Other Related Factors.
- Author
-
Carullo, Nazareno, Sorbo, David, Faga, Teresa, Pugliese, Sara, Zicarelli, Maria Teresa, Costa, Davide, Ielapi, Nicola, Battaglia, Yuri, Pisani, Antonio, Coppolino, Giuseppe, Bolignano, Davide, Michael, Ashour, Serra, Raffaele, and Andreucci, Michele more...
- Abstract
Anemia and mineral and bone disorder (MBD) are significant complications of chronic kidney disease (CKD). The erythropoietin (Epo) pathway plays a key role in both of these processes in CKD. Another molecule that plays an important role in CKD-MBD is fibroblast growth factor (FGF)-23, whose main role is to maintain serum phosphate levels in the normal range, acting via its co-receptor Klotho; however, its activity may also be related to anemia and inflammation. In this review, the regulation of Epo and FGF-23 and the molecular mechanisms of their action are outlined. Furthermore, the complex interaction between EPO and FGF-23 is discussed, as well as their association with other anemia-related factors and processes such as Klotho, vitamin D, and iron deficiency. Together, these may be part of a "kidney–bone marrow–bone axis" that promotes CKD-MBD. [ABSTRACT FROM AUTHOR] more...
- Published
- 2024
- Full Text
- View/download PDF